CANTON, Conn., Nov. 10, 2025 /PRNewswire/ -- Kelyniam Global, Inc. (OTC:KLYG), a leader in custom cranial and craniofacial implants, today reported financial results for the third quarter ended September 30, 2025.

Q3 2025 Financial Highlights (Compared to Q3 2024)

Year-to-date revenue of $2,186,491, compared to $2,492,607, a decrease of 12.3%.

Gross profit of $1,695,496, compared to $1,956,714, a decrease of 13.3%, primarily due to the revenue headwinds offset by stable material costs.

Operating loss of $(162,373), compared to operating income of $273,248, reflecting increased investments in sales support and regulatory costs associated with the new Vestakeep® product.

"Sales have faced headwinds this year from a slow distributor ramp-up and temporary market share shifts, but through Q3, we're steadily catching up to 2024 levels and building a stronger foundation for sustainable growth," said Ross Bjella, CEO ...